financetom
Business
financetom
/
Business
/
Relmada says independent analysis shows depression treatment unlikely to meet main trial goal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Relmada says independent analysis shows depression treatment unlikely to meet main trial goal
Dec 4, 2024 5:02 AM

Dec 4 (Reuters) - Relmada Therapeutics ( RLMD ) said on

Wednesday its treatment for a major depressive disorder is

"unlikely" to meet the main goal of a late-stage trial,

according to an independent data monitoring committee's

analysis.

(Reporting by Christy Santhosh in Bengaluru)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved